NCT04073680View on ClinicalTrials.gov

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

July 15, 2021

Study Completion Date

December 30, 2021

Conditions
Breast CancerEndometrial CancerLung CancerColo-rectal CancerHead and Neck Cancer
Interventions
DRUG

Serabelisib

Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications

DRUG

Canagliflozin 300mg

All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib

Sponsors

Lead Sponsor

Petra Pharma
All Listed Sponsors
lead

Petra Pharma

INDUSTRY